Reduced-frequency dosing case series published in Obesity

Researchers have published what appears to be the first clinical data on "spaced" GLP-1 dosing: a retrospective case series of 30 adults who had hit a weight plateau on once-weekly semaglutide or tirzepatide and then switched to less frequent injections, usually every other week, without changing the amount in each dose ^[1]. Over an average of 36.3 weeks on the reduced-frequency schedule, the group maintained their weight loss, body composition gains and metabolic improvements ^[1]. JAMA covered the finding in a news item summarizing that reduced-frequency dosing "may sustain treatment effects" ^[2].

What the study measured

The authors collected data at three points: before GLP-1 treatment, at the weight plateau on weekly dosing, and during the maintenance phase on reduced-frequency dosing ^[1]. Average weight fell from 87.9 ± 2.4 kg before treatment to 74.1 ± 2.4 kg at plateau, then edged down further to 72.4 ± 2.2 kg during reduced-frequency maintenance (p < 0.01) ^[1]. That is roughly 13.8 kg lost during the weekly phase and another 1.7 kg during the spaced-dosing phase, on average.

Body composition was measured with bioelectrical impedance. Total body fat and truncal fat declined, while skeletal muscle mass stabilized on the reduced-frequency regimen ^[1]. Not everyone had body composition data at every visit: the figure legends list 23 patients pre-treatment, 24 at plateau and 20 at maintenance ^[1]. Metabolic syndrome measures — including BMI, HbA1c, triglycerides, HDL cholesterol and blood pressure — improved during weekly dosing, and those gains held during reduced-frequency therapy, with data available for 25 to 29 patients depending on the measure ^[1].

The authors conclude that in patients who had already lost weight and improved metabolically on GLP-1 therapy, reduced-frequency maintenance dosing "preserved outcomes," and they describe structured de-escalation as "a promising strategy to reduce treatment burden without sacrificing efficacy" ^[1]. The paper was published in Obesity, the journal of The Obesity Society ^[1]. One author disclosed working as a clinical trial site investigator for GLP-1 agents for Eli Lilly and Novo Nordisk; the others reported no conflicts ^[1].

The limits are large

This is a case series, not a randomized trial. There was no control group kept on weekly dosing for comparison, so there is no way to know from this design whether the 30 patients would have done the same, better or worse had they stayed on their weekly schedule. The sample is small, the data were collected retrospectively, and the reduced-frequency schedules were patient-reported rather than assigned by protocol, according to the study's case flowchart description ^[1].

Some details widely discussed alongside the paper are not in the published abstract. The abstract does not state how many patients went back to weekly dosing after regaining weight, how doses were chosen, what happened to side effects, or how the 30 included patients were selected from a larger group ^[1]. The JAMA item listed in PubMed carries no abstract, so its full text is not available in the sources reviewed here ^[2].

Why it matters for patients

Stretching the interval between injections is already something many people do informally, often because of cost, supply gaps, insurance changes or side effects. Until now, the evidence behind it was largely theoretical. This series gives clinicians a first data point suggesting that, for people who have already plateaued, every-other-week dosing at the same strength may hold results for the better part of a year ^[1].

It does not establish that this works for most people, or that it is safe to try without medical supervision. The study looked only at patients who had reached a plateau after successful weekly treatment — not at people still losing weight, still titrating up, or using these drugs mainly for diabetes or heart risk ^[1]. Semaglutide and tirzepatide are approved for once-weekly use; alternate-week dosing is off-label and outside what the labels describe.

Also worth noting: average weight kept drifting down slightly on the spaced schedule, which suggests the study population may have been people for whom the approach worked, rather than a representative cross-section ^[1].

What happens next

The authors frame structured de-escalation as a strategy worth studying rather than a proven protocol ^[1]. Randomized comparisons of weekly versus reduced-frequency maintenance dosing would be the next step, and no such trial results are reported in these sources. Whether payers or prescribers will treat spaced dosing as an accepted maintenance option is not yet known.